Entera Bio Ltd. - ENTX
About Gravity Analytica
Recent News
- 10.21.2025 - October 21, 2025 - October 25, 2025 : The Menopause Society 2025 Annual Meeting (Poster)
- 10.16.2025 - Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
- 09.15.2025 - Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congresse Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
- 09.15.2025 - Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
- 09.15.2025 - Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
- 09.13.2025 - 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress (Poster)
- 09.08.2025 - Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
- 09.08.2025 - Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
- 09.08.2025 - Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025
- 09.07.2025 - American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting (Poster and 1×1)